Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Cools

Showing results (61-70 of 184) with videos related to

Pageof 19
Sort By:
Haematologica|March 31, 2022
TAL1 cooperates with PI3K/AKT pathway activation in T-cell acute lymphoblastic leukemiaNaomi Thielemans, Sofie Demeyer, Nicole Mentens, et al.
Haematologica|January 19, 2007
The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitorsEls Lierman, Idoya Lahortiga, Helen Van Miegroet, et al.
Blood|September 11, 2007
Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurinElly V Barry, Jennifer J Clark, Jan Cools, et al.
Haematologica|June 8, 2006
Fusion of ETV6 to GOT1 in a case with myelodysplastic syndrome and t(10;12)(q24;p13)Hilde Janssen, Iwona Wlodarska, Cristina Mecucci, et al.
Acta Oncologica (Stockholm, Sweden)|September 18, 2013
FLT1 kinase is a mediator of radioresistance and survival in head and neck squamous cell carcinomaEvert Jan Van Limbergen, Piotr Zabrocki, Michaël Porcu, et al.
Haematologica|August 1, 2009
The fusion proteins TEL-PDGFRbeta and FIP1L1-PDGFRalpha escape ubiquitination and degradationFederica Toffalini, Anders Kallin, Peter Vandenberghe, et al.
Haematologica|January 26, 2023
Combination therapy of a PSEN1-selective γ-secretase inhibitor with dexamethasone and an XPO1 inhibitor to target T-cell acute lymphoblastic leukemiaCharlien Vandersmissen, Cristina Prieto, Olga Gielen, et al.
Blood|April 9, 2004
The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and managementJason Gotlib, Jan Cools, James M Malone, et al.
Haematologica|July 28, 2011
Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin's lymphoma and T-cell non-Hodgkin's lymphomaMaria Kleppe, Thomas Tousseyn, Eva Geissinger, et al.
Blood|February 28, 2002
Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13)Jan Cools, Nicole Mentens, Maria D Odero, et al.
Pageof 19

Showing results (61-70 of 184) with videos related to

Sort By:
Pageof 19
Haematologica|March 31, 2022
TAL1 cooperates with PI3K/AKT pathway activation in T-cell acute lymphoblastic leukemiaNaomi Thielemans, Sofie Demeyer, Nicole Mentens, et al.
Haematologica|January 19, 2007
The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitorsEls Lierman, Idoya Lahortiga, Helen Van Miegroet, et al.
Blood|September 11, 2007
Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurinElly V Barry, Jennifer J Clark, Jan Cools, et al.
Haematologica|June 8, 2006
Fusion of ETV6 to GOT1 in a case with myelodysplastic syndrome and t(10;12)(q24;p13)Hilde Janssen, Iwona Wlodarska, Cristina Mecucci, et al.
Acta Oncologica (Stockholm, Sweden)|September 18, 2013
FLT1 kinase is a mediator of radioresistance and survival in head and neck squamous cell carcinomaEvert Jan Van Limbergen, Piotr Zabrocki, Michaël Porcu, et al.
Haematologica|August 1, 2009
The fusion proteins TEL-PDGFRbeta and FIP1L1-PDGFRalpha escape ubiquitination and degradationFederica Toffalini, Anders Kallin, Peter Vandenberghe, et al.
Haematologica|January 26, 2023
Combination therapy of a PSEN1-selective γ-secretase inhibitor with dexamethasone and an XPO1 inhibitor to target T-cell acute lymphoblastic leukemiaCharlien Vandersmissen, Cristina Prieto, Olga Gielen, et al.
Blood|April 9, 2004
The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and managementJason Gotlib, Jan Cools, James M Malone, et al.
Haematologica|July 28, 2011
Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin's lymphoma and T-cell non-Hodgkin's lymphomaMaria Kleppe, Thomas Tousseyn, Eva Geissinger, et al.
Blood|February 28, 2002
Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13)Jan Cools, Nicole Mentens, Maria D Odero, et al.
Pageof 19